Skip to content

Real-world Study of San Sang Shen Qi Decoction Combined with Liuzijue qigong in the Treatment of Shenqi Deficiency Syndrome in Moderate-severe Stable COPD

Real-world Study of San Sang Shen Qi Decoction Combined with Liuzijue qigong in the Treatment of Shenqi Deficiency Syndrom in Moderate-severe Stable COPD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085905
Enrollment
Unknown
Registered
2024-06-20
Start date
2024-07-01
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

Traditional Chinese medicine group:Combining standard medical treatment with San Sang Shen Qi Decoction
Combining traditional Chinese medicine group with Qi Gong:Combining standard medical treatment with San Sang Shen Qi Decoction and Liuzijue qigong

Sponsors

Traditional Chinese Medicine Hospital Fengxian Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Patients of any gender, aged between 40 and 85 years old; (2) Accord with that diagnostic criteria for chronic obstructive pulmonary disease (COPD) and have a predicted FEV1 value between 30% and 80%; (3) Accord with that diagnostic criteria for traditional Chinese medicine differentiation; (4) Conscious and hemodynamically stable; (5) Willing to participate in this study and sign an informed consent file.

Exclusion criteria

Exclusion criteria: (1) Lung diseases with known causes or specific pathological presentations that result in airflow obstruction, such as cystic fibrosis, diffuse panbronchiolitis, etc; (2) Patients with concomitant lung diseases such as pulmonary tuberculosis, malignant lung tumors, etc; (3) Patients with respiratory failure, severe cardiac, hepatic, or renal insufficiency; (4) Patients with a history of hypersensitivity or allergic reactions to the investigational drugs in this trial;(5) Patients in the acute exacerbation phase of chronic obstructive pulmonary disease (COPD);(6) Patients currently participating in other clinical trials that may affect the evaluation of the results of this study.

Design outcomes

Primary

MeasureTime frame
FEV1%;

Secondary

MeasureTime frame
diaphragmatic excursion;frequency of acute exacerbations;SF36 Quality of Life Scale;TCM symptom score ;

Countries

China

Contacts

Public ContactWenyan Gu

Traditional Chinese Medicine Hospital Fengxian Shanghai

guwenyan89@163.com+86 139 1739 4337

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026